Compare HP Inc (HPQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? HP Inc trades at $30.74 (market cap $29.25B), while Vertex Pharmaceuticals Incorporated trades at $513.16 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.4× HP Inc's market cap, and HP Inc pays a 3.7% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| HPQ | VRTX | |
|---|---|---|
Market Cap | $29.25B | $127.55B |
Volume | 10,025,806 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $35.48 | $557.96 |
52-Week Low | $18.20 | $407.37 |
Typical Hold Time | 70 Days | 120 Days |
Enterprise Value | $35.42B | $121.68B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $32.24, up 1.61% with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, maintaining stable revenue around $55B with a 4.14% net margin. Recent news highlights HP's new PC launches and AI capabilities, though the stock faces headwinds from a projected mid-single-digit PC market decline in 2027.
The outlook is mixed: valuation appears reasonable with a P/E of 12.38 and P/S of 0.51, and strong cash flow supports dividends. However, negative shareholder equity and competitive pressures in the PC market present risks. Analyst consensus is cautious with a $25.75 price target below current levels, suggesting limited near-term upside.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
